Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that Nuvaxovid&tra...
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO...
Veeva Systems (NYSE: VEEV) announced that leaders from Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, and Syneos Health are among the speak...
Beren is a vertically integrated biopharmaceutical company focused on addressing the world’s most significant health challenges. Roquette recognizes ...
Humanetics Biomed is a Contract Development Manufacturing Organisation (CDMO) that combines the best biomedical technologies from Humanetics; with the tech...
“We are thrilled to partner with BeiGene to help people living with CLL in low- and middle-income countries have access to BRUKINSA,” said Pat ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, celebrates today with longstanding partner, Da...
The NDA is based on the results of the Phase 3 Clarity AD study and the Phase 2b clinical study, which demonstrated that lecanemab treatment showed a reduc...
GE HealthCare (Nasdaq: GEHC) is presenting three new global innovations – Intelligent Radiation Therapy (iRT), Auto Segmentation, and an updated Magn...
Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039. The allowed claims cover MN...
As a Siemens Healthineers company, Varian is working to connect the cancer care continuum to empower clinicians to deliver more efficient, more personalize...
Veeva Systems (NYSE: VEEV) today announced that Sanofi is implementing Veeva Vault QMS and Veeva Vault QualityDocs to modernize quality management across t...
UCB's expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum's discovery of t...
Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardi...
© 2025 Biopharma Boardroom. All Rights Reserved.
